Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

Christie M. Ballantyne, Ron C. Hoogeveen, Heejung Bang, Josef Coresh, Aaron R. Folsom, Lloyd E. Chambless, Merle Myerson, Kenneth K. Wu, A. Richey Sharrett, Eric Boerwinkle

Research output: Contribution to journalArticle

243 Citations (Scopus)

Abstract

Background: Measurement of inflammatory markers has been reported to identify individuals at increased risk for ischemic stroke. Lipoprotein- associated phospholipase A2 (Lp-PLA2) is a proinflammatory enzyme secreted by macrophages. We assessed Lp-PLA2 and C-reactive protein (CRP) levels along with traditional risk factors to examine their relation to ischemic stroke. Methods: A proportional hazards model was used in prospective case-cohort study of 12 762 apparently healthy middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study who were observed for about 6 years. Results: Mean Lp-PLA2 and CRP levels adjusted for sex, race, and age were higher in the 194 stroke cases than the 766 noncases, whereas low-density lipoprotein cholesterol (LDL-C) level was not significantly different. Both Lp-PLA2 and CRP levels were associated with ischemic stroke after adjustment for age, sex, and race: hazard ratios were 2.23 for the highest vs the lowest tertile of Lp-PLA2 and 2.70 for CRP level higher than 3 vs lower than 1 mg/L. In a model that included smoking, systolic hypertension, lipid levels, and diabetes, Lp-PLA2 and CRP levels in the highest category were associated with hazard ratios of 1.91 (95% confidence interval, 1.15-3.18;P=.01) and 1.87 (95%confidence interval, 1.13-3.10;P=.02), respectively. Individuals with high levels of both CRP and Lp-PLA2 were at the highest risk after adjusting for traditional risk factors compared with individuals with low levels of both, whereas others were at intermediate risk. Conclusion: Levels of Lp-PLA2 and CRP may be complementary beyond traditional risk factors in identifying middle-aged individuals at increased risk for ischemic stroke.

Original languageEnglish (US)
Pages (from-to)2479-2484
Number of pages6
JournalArchives of Internal Medicine
Volume165
Issue number21
DOIs
StatePublished - Nov 28 2005
Externally publishedYes

Fingerprint

1-Alkyl-2-acetylglycerophosphocholine Esterase
C-Reactive Protein
Atherosclerosis
Stroke
Type C Phospholipases
Confidence Intervals
Proportional Hazards Models
LDL Cholesterol
Cohort Studies
Smoking
Macrophages
Hypertension
Lipids

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. / Ballantyne, Christie M.; Hoogeveen, Ron C.; Bang, Heejung; Coresh, Josef; Folsom, Aaron R.; Chambless, Lloyd E.; Myerson, Merle; Wu, Kenneth K.; Sharrett, A. Richey; Boerwinkle, Eric.

In: Archives of Internal Medicine, Vol. 165, No. 21, 28.11.2005, p. 2479-2484.

Research output: Contribution to journalArticle

Ballantyne, Christie M. ; Hoogeveen, Ron C. ; Bang, Heejung ; Coresh, Josef ; Folsom, Aaron R. ; Chambless, Lloyd E. ; Myerson, Merle ; Wu, Kenneth K. ; Sharrett, A. Richey ; Boerwinkle, Eric. / Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. In: Archives of Internal Medicine. 2005 ; Vol. 165, No. 21. pp. 2479-2484.
@article{2d344a20d90f4b9badc2c9522ad581fd,
title = "Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study",
abstract = "Background: Measurement of inflammatory markers has been reported to identify individuals at increased risk for ischemic stroke. Lipoprotein- associated phospholipase A2 (Lp-PLA2) is a proinflammatory enzyme secreted by macrophages. We assessed Lp-PLA2 and C-reactive protein (CRP) levels along with traditional risk factors to examine their relation to ischemic stroke. Methods: A proportional hazards model was used in prospective case-cohort study of 12 762 apparently healthy middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study who were observed for about 6 years. Results: Mean Lp-PLA2 and CRP levels adjusted for sex, race, and age were higher in the 194 stroke cases than the 766 noncases, whereas low-density lipoprotein cholesterol (LDL-C) level was not significantly different. Both Lp-PLA2 and CRP levels were associated with ischemic stroke after adjustment for age, sex, and race: hazard ratios were 2.23 for the highest vs the lowest tertile of Lp-PLA2 and 2.70 for CRP level higher than 3 vs lower than 1 mg/L. In a model that included smoking, systolic hypertension, lipid levels, and diabetes, Lp-PLA2 and CRP levels in the highest category were associated with hazard ratios of 1.91 (95{\%} confidence interval, 1.15-3.18;P=.01) and 1.87 (95{\%}confidence interval, 1.13-3.10;P=.02), respectively. Individuals with high levels of both CRP and Lp-PLA2 were at the highest risk after adjusting for traditional risk factors compared with individuals with low levels of both, whereas others were at intermediate risk. Conclusion: Levels of Lp-PLA2 and CRP may be complementary beyond traditional risk factors in identifying middle-aged individuals at increased risk for ischemic stroke.",
author = "Ballantyne, {Christie M.} and Hoogeveen, {Ron C.} and Heejung Bang and Josef Coresh and Folsom, {Aaron R.} and Chambless, {Lloyd E.} and Merle Myerson and Wu, {Kenneth K.} and Sharrett, {A. Richey} and Eric Boerwinkle",
year = "2005",
month = "11",
day = "28",
doi = "10.1001/archinte.165.21.2479",
language = "English (US)",
volume = "165",
pages = "2479--2484",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "21",

}

TY - JOUR

T1 - Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

AU - Ballantyne, Christie M.

AU - Hoogeveen, Ron C.

AU - Bang, Heejung

AU - Coresh, Josef

AU - Folsom, Aaron R.

AU - Chambless, Lloyd E.

AU - Myerson, Merle

AU - Wu, Kenneth K.

AU - Sharrett, A. Richey

AU - Boerwinkle, Eric

PY - 2005/11/28

Y1 - 2005/11/28

N2 - Background: Measurement of inflammatory markers has been reported to identify individuals at increased risk for ischemic stroke. Lipoprotein- associated phospholipase A2 (Lp-PLA2) is a proinflammatory enzyme secreted by macrophages. We assessed Lp-PLA2 and C-reactive protein (CRP) levels along with traditional risk factors to examine their relation to ischemic stroke. Methods: A proportional hazards model was used in prospective case-cohort study of 12 762 apparently healthy middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study who were observed for about 6 years. Results: Mean Lp-PLA2 and CRP levels adjusted for sex, race, and age were higher in the 194 stroke cases than the 766 noncases, whereas low-density lipoprotein cholesterol (LDL-C) level was not significantly different. Both Lp-PLA2 and CRP levels were associated with ischemic stroke after adjustment for age, sex, and race: hazard ratios were 2.23 for the highest vs the lowest tertile of Lp-PLA2 and 2.70 for CRP level higher than 3 vs lower than 1 mg/L. In a model that included smoking, systolic hypertension, lipid levels, and diabetes, Lp-PLA2 and CRP levels in the highest category were associated with hazard ratios of 1.91 (95% confidence interval, 1.15-3.18;P=.01) and 1.87 (95%confidence interval, 1.13-3.10;P=.02), respectively. Individuals with high levels of both CRP and Lp-PLA2 were at the highest risk after adjusting for traditional risk factors compared with individuals with low levels of both, whereas others were at intermediate risk. Conclusion: Levels of Lp-PLA2 and CRP may be complementary beyond traditional risk factors in identifying middle-aged individuals at increased risk for ischemic stroke.

AB - Background: Measurement of inflammatory markers has been reported to identify individuals at increased risk for ischemic stroke. Lipoprotein- associated phospholipase A2 (Lp-PLA2) is a proinflammatory enzyme secreted by macrophages. We assessed Lp-PLA2 and C-reactive protein (CRP) levels along with traditional risk factors to examine their relation to ischemic stroke. Methods: A proportional hazards model was used in prospective case-cohort study of 12 762 apparently healthy middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study who were observed for about 6 years. Results: Mean Lp-PLA2 and CRP levels adjusted for sex, race, and age were higher in the 194 stroke cases than the 766 noncases, whereas low-density lipoprotein cholesterol (LDL-C) level was not significantly different. Both Lp-PLA2 and CRP levels were associated with ischemic stroke after adjustment for age, sex, and race: hazard ratios were 2.23 for the highest vs the lowest tertile of Lp-PLA2 and 2.70 for CRP level higher than 3 vs lower than 1 mg/L. In a model that included smoking, systolic hypertension, lipid levels, and diabetes, Lp-PLA2 and CRP levels in the highest category were associated with hazard ratios of 1.91 (95% confidence interval, 1.15-3.18;P=.01) and 1.87 (95%confidence interval, 1.13-3.10;P=.02), respectively. Individuals with high levels of both CRP and Lp-PLA2 were at the highest risk after adjusting for traditional risk factors compared with individuals with low levels of both, whereas others were at intermediate risk. Conclusion: Levels of Lp-PLA2 and CRP may be complementary beyond traditional risk factors in identifying middle-aged individuals at increased risk for ischemic stroke.

UR - http://www.scopus.com/inward/record.url?scp=28344441841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28344441841&partnerID=8YFLogxK

U2 - 10.1001/archinte.165.21.2479

DO - 10.1001/archinte.165.21.2479

M3 - Article

C2 - 16314544

AN - SCOPUS:28344441841

VL - 165

SP - 2479

EP - 2484

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 21

ER -